adplus-dvertising

Progress on mRNA Tx for HF; Neighborhood OHCA Watch; ‘Dragon’s Blood’ Antiplatelet?

mRNA therapy for heart failure passed an early safety hurdle, but efficacy remains an open question. (Endpoints News)

Rigorous testing of sodium and potassium intake, based on multiple 24-hour urine samples, confirmed sodium’s association with greater cardiovascular risk and the opposite for potassium. (New England Journal of Medicine)

Putting a venous external support device over saphenous vein grafts showed mixed results at prolonging graft durability after coronary artery bypass surgery, according to a small trial presented at the American Heart Association (AHA) annual meeting.

Regardless of diabetes status, heart failure symptoms were improved with the SGLT2 inhibitor canagliflozin (Invokana) in the CHIEF-HF trial presented at AHA.

Also at AHA, a large trial in rural China found that intervention by community health workers improved blood pressure control for villagers with uncontrolled hypertension.

For cardiac arrests occurring in homes, a system of neighborhood volunteer responders led to faster CPR and ultimately resulted in improved survival in the Netherlands. (European Heart Journal)

Introducing the Mehran-2 CA-AKI Risk Score for predicting contrast-associated acute kidney injury after percutaneous coronary intervention. (The Lancet)

People with atrial fibrillation were less likely to perceive their symptoms amid their quality-of-life issues if they had diabetes. (Journal of the American Heart Association)

The novel PCSK9 inhibitor tafolecimab showed promise in lowering LDL cholesterol in preliminary studies. (JACC: Asia)

Preoperative pulmonary artery dilatation on CT was associated with mortality within 2 years after transcatheter aortic valve replacement. (JACC: Cardiovascular Interventions)

White and Black patients alike benefited from dapagliflozin (Farxiga) for heart failure with reduced ejection fraction in the DAPA-HF trial. (JACC: Heart Failure)

One group examined sex-specific differences in heart failure and urged future research. (Journal of Cardiac Failure)

Among the various lipid parameters, apoB-containing lipoproteins stood out for their prognostic value in predicting myocardial infarction. (JAMA Cardiology)

FDA gave 510(k) clearance to the vMap arrhythmia hotspot mapping software, Vektor Medical announced.

Taiwan is suspending second doses of Pfizer’s COVID-19 mRNA vaccine for children ages 12 to 17, citing an ongoing investigation into myocarditis cases. (Taiwan News)

The lack of antitachycardia pacing in a subcutaneous implantable cardioverter-defibrillator (ICD) did not detract from its shock efficacy compared with a transvenous ICD in the PRAETORIAN trial. (Circulation)

The benefit of endovascular therapy for acute basilar artery occlusion strokes continued to hold up at 1 year in an observational study, though over half of treated patients had died by then. (Stroke)

Is triptan use by migraine patients linked to spontaneous coronary artery dissection? (Journal of the American College of Cardiology)

Scientists probe the anti-clotting properties of a compound isolated from the traditional herbal medicine “Dragon’s Blood.” (Journal of Thrombosis and Haemostasis)

A Texas cardiologist defended himself in response to a lawsuit alleging a conspiracy by his group to intimidate other cardiologists from moving into town. (Laredo Morning Times)

  • Nicole Lou is a reporter for MedPage Today, where she covers cardiology news and other developments in medicine. Follow

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.